LSX Congress USA is where biotech companies from emerging startups to later-stage firms meet investors and pharma partners to power the next stage of growth. Attendees engage in 1:1 partnering, focused discussions on capital raising, investment strategies, commercialisation and pharma partnerships in the US life sciences sector. With tailored tracks, network…
- Understanding what biotech investors prioritize when evaluating Seed and Series A funding opportunities - Effectively communicate your vision and scientific potential to attract …
South Florida is solidifying its position as a national healthcare and life sciences hub. With its strategic location, growing infrastructure, and influx of investment, the city is…
- Identifying high-growth regions and market opportunities - Navigating regulatory landscapes and compliance challenges - Building strategic partnerships to accelerate market entry
- Streamlining the journey from research to clinical application - Overcoming regulatory and operational hurdles in drug development - Enhancing patient access to life-saving thera…
- Strategies for fostering successful cross-border collaborations in the biopharma industry - Key considerations and challenges in out-licensing agreements across global markets - …
- What’s had investors talking in 2026? - How are we thinking about innovation in the current climate - Every investor’s number one priority (or should be)
- Crafting a compelling value proposition that resonates with investors - Understanding the unique funding challenges in the medtech sector - Preparing for regulatory hurdles that …
What does it mean when 179 companies show up — and 3 bet on three roles at once?
The numbers below are derived from the speakers, sponsors, and exhibitors on this page — cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.
The Triple-Threat
86% of the speakers carry senior titles — C-suite, Founder, VP, or Director-level.
Of 174 on the bill · classified by free-text title